Reini Juhani Hurme
Directeur Général chez Zora Biosciences Oy
Profil
Reini Juhani Hurme is the founder and is the Chief Executive Officer of Zora Biosciences Oy, which is founded in 2006.
He also held the position of Principal at Leiras Oy and Schering Oy.
Postes actifs de Reini Juhani Hurme
| Sociétés | Poste | Début |
|---|---|---|
Zora Biosciences Oy
 Zora Biosciences Oy Medical/Nursing ServicesHealth Services Zora Biosciences Oy develops biomarker-based diagnostics tests. It focuses on cardiovascular disease. The company's main product is coronary event risk test. Zora Biosciences was founded by Reini Juhani Hurme, Reijo Laaksonen, and Matej Orešic on December 14, 2006 and is headquartered in Espoo, Finland. | Directeur Général | 14/12/2006 |
Anciens postes connus de Reini Juhani Hurme
| Sociétés | Poste | Fin |
|---|---|---|
| Schering Oy | Corporate Officer/Principal | - |
Leiras Oy
 Leiras Oy Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Leiras Oy is a Finnish company that develops pharmaceutical solutions. The company is based in Turku, Finland. Leiras was acquired by Nycomed Pharma Holding A/S on May 31, 2003 for $49.44 million. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Zora Biosciences Oy
Zora Biosciences Oy Medical/Nursing ServicesHealth Services Zora Biosciences Oy develops biomarker-based diagnostics tests. It focuses on cardiovascular disease. The company's main product is coronary event risk test. Zora Biosciences was founded by Reini Juhani Hurme, Reijo Laaksonen, and Matej Orešic on December 14, 2006 and is headquartered in Espoo, Finland. | Health Services |
Leiras Oy
Leiras Oy Pharmaceuticals: MajorHealth Technology Part of Bayer AG, Leiras Oy is a Finnish company that develops pharmaceutical solutions. The company is based in Turku, Finland. Leiras was acquired by Nycomed Pharma Holding A/S on May 31, 2003 for $49.44 million. | Health Technology |
| Schering Oy |
